Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY - Get Free Report) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $57.34 and last traded at $57.33, with a volume of 2748 shares. The stock had previously closed at $56.93.
Wall Street Analyst Weigh In
Separately, Royal Bank Of Canada raised shares of Sandoz Group from a "hold" rating to a "moderate buy" rating in a research note on Friday, May 2nd.
View Our Latest Analysis on SDZNY
Sandoz Group Price Performance
The firm has a fifty day moving average price of $52.08 and a 200 day moving average price of $46.58. The company has a quick ratio of 0.79, a current ratio of 1.24 and a debt-to-equity ratio of 0.57.
About Sandoz Group
(
Get Free Report)
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sandoz Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sandoz Group wasn't on the list.
While Sandoz Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
